Evidence map›Paper›PMID 33252616›Full record

ArticleJAMA internal medicine2021

Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine.

Natalie McCormick, Zachary S Wallace, Chio Yokose, April Jorge, Chana A Sacks, John Hsu, Hyon K Choi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAMA internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Natalie McCormickClinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.
Zachary S WallaceClinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.
Chio YokoseClinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.
April JorgeClinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.
Chana A SacksDivision of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
John HsuDepartment of Health Care Policy, Massachusetts General Hospital, Harvard Medical School, Boston.
Hyon K ChoiClinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.

Funding

The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2012 to 2021
$12.8M
Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9M
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948k
NIAMS NIH HHS K23 AR073334NIAMS NIH HHS P50 AR060772NIAMS NIH HHS T32 AR007258
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular AgentsColchicineDrug ApprovalDrugs, GenericHumansMedicaidMedicareUnited StatesUnited States Food and Drug AdministrationCardiovascular AgentsColchicineDrugs, Generic

Identifiers

PMID33252616
PMCPMC7851728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.